(-1.41%) 5 000.05 points
(-1.78%) 37 775 points
(-1.81%) 15 429 points
(-0.71%) $82.22
(-1.15%) $1.634
(0.71%) $2 355.00
(0.73%) $27.55
(0.60%) $921.30
(-0.11%) $0.933
(0.10%) $10.99
(-0.23%) $0.801
(-0.40%) $91.95
Live Chart Being Loaded With Signals
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health...
Stats | |
---|---|
Today's Volume | 246 141 |
Average Volume | 196 980 |
Market Cap | 29.04M |
EPS | €0 ( 2024-04-17 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.456 |
ATR14 | €0.0560 (9.49%) |
Volume Correlation
Nicox SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nicox SA Correlation - Currency/Commodity
Nicox SA Financials
Annual | 2022 |
Revenue: | €5.24M |
Gross Profit: | €3.27M (62.40 %) |
EPS: | €0 |
Q4 | 2013 |
Revenue: | €495 000 |
Gross Profit: | €271 000 (54.75 %) |
EPS: | €-0.296 |
Q3 | 2013 |
Revenue: | €69 000.00 |
Gross Profit: | €-47 000.00 (-68.12 %) |
EPS: | €-0.291 |
Q2 | 2013 |
Revenue: | €114 000 |
Gross Profit: | €-23 000.00 (-20.18 %) |
EPS: | €-0.333 |
Financial Reports:
No articles found.
Nicox SA
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators